PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Fulton, B, Short, SC orcid.org/0000-0003-4423-7256, James, A et al. (8 more authors) (2018) PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology, 8. pp. 12-16. ISSN 2405-6308

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: (c) 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Glioblastoma; Poly(ADP-ribose) polymerase; Olaparib; Radiotherapy; O6-methylguanine methyltransferase; Dose escalation; Radiosensitizer
Dates:
  • Accepted: 17 November 2017
  • Published (online): 21 November 2017
  • Published: January 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 15 Aug 2018 11:21
Last Modified: 15 Aug 2018 11:21
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.ctro.2017.11.003

Export

Statistics


CORE (COnnecting REpositories)